Skip to content

Get Involved

 

Be a Volunteer

We need your help! The Lone Star Bleeding Disorders Foundation has many opportunities to get involved. Please join us! Volunteer at an event. 

CONTACT US

 

 

Be a Donor

Attend and/or donate to Casino Night, Hemophilia Walk, or make a general donation to the Lone Star Bleeding Disorders Foundation. Funds raised go towards each of our programs, Camp Ailihpomeh, Texas Bleeding Disorders Conference, and our B’Leaders Teen Program. Ask your company’s personnel department if they participate in employee matching and double your donation.

DONATE

 

 

Be a Member

 

Become a member of the Lone Star Bleeding Disorders Foundation and receive our Factor Friends Newsletter, and invitations to our events. Attend the Texas Bleeding Disorders Conference, a Hemophilia Walk in your area, or a Family Education Day.

CONTACT US

News from HFA

  • Word from Washington: May 2023

    Lawmakers in May devoted close attention to the role that pharmacy benefits managers (PBMs) play in our health care system.  PBMs are middlemen that create and administer drug formularies on behalf of health insurers, self-insured employers, Medicaid, and other payers. PBMs choose which drugs a plan will cover, negotiate drug prices on behalf of payers, The post Word from Washington: May 2023 appeared first on Hemophilia Federation of America.

  • Pfizer Announces Positive Results from Hemophilia A and B Trial

    Pfizer Inc. today announced their Phase 3 BASIS clinical trial evaluating marstacimab has met its primary endpoints, having demonstrated statically significant and clinically meaningful effects. Marstacimab, a novel, investigational anti-tissue factor pathway inhibitor (anti-TFPI) being studied for the treatment of hemophilia A or B for people without inhibitors to Factor VIII (FVIII) or Factor IX The post Pfizer Announces Positive Results from Hemophilia A and B Trial appeared first on Hemophilia Federation of America.

  • FDA Finalizes Blood Donor Eligibility Guidance

    On May 11, 2023, the U.S. Food and Drug Administration released final guidance providing recommendations for evaluating blood and plasma donor eligibility using individual risk-based questions. Consistent with FDA’s January 2023 proposed guidance, the final guidance eliminates time-based donation deferrals and screening questions specific to men who have sex with men (MSM) and women who have The post FDA Finalizes Blood Donor Eligibility Guidance appeared first on Hemophilia Federation of America.

  • FDA issues response to Novo Nordisk’s request for concizumab approval

    Recently Novo Nordisk received a Complete Response Letter from the Food and Drug Administration for concizumab. Concizumab was submitted for regulatory approval in the U.S. for the treatment of hemophilia A and B with inhibitors in August 2022. In the letter, the FDA requested additional information related to the monitoring and dosing of patients to The post FDA issues response to Novo Nordisk’s request for concizumab approval appeared first on Hemophilia Federation of America.

  • The HELP Copays Act moves forward – now in the Senate as well as in the House 

    Protections for people who rely on copay assistance have been a top priority for HFA and many other patient groups for several years. That effort took a big step forward in April with the introduction of a first-ever Senate version (S. 1375) of the HELP Copays Act.   Sponsored by Sens. Kaine, Marshall, Markey, and Ernst, The post The HELP Copays Act moves forward – now in the Senate as well as in the House  appeared first on Hemophilia Federation of America.